• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ENTA

ENTA

Enanta Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD11.24

-0.79 (-6.57%)

Rating:D+

Company Profile

CEO

Jay R. Luly

IPO Date

2013-03-21

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$11.92

Prev. Close

$12.03

Day Low

$11.17

Day High

$12.03

52W Low

$6.43

52W High

$17.15

Market Cap

$0.26B

Volume

0.37M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

25.4%

Avg Negative

7.1%

Avg Neutral

67.4%

News Feed

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

Business Wire·8/23/2021·↑ positive

Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call Transcript

Seeking Alpha·8/8/2021·↓ negative

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

Business Wire
·8/5/2021
·↑ positive

Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.

Business Wire·7/14/2021·↓ negative

Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™

Business Wire·6/23/2021·↑ positive

Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·5/10/2021·↓ negative

Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA

Benzinga·5/7/2021·↑ positive

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

The Bottom Fishing Club: Enanta Pharmaceuticals

Seeking Alpha·3/8/2021·↑ positive

Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

Business Wire·3/2/2021·↑ positive